Nanobiotix S.A. (NBTX) SEC Filings

Nanobiotix S.A. (NBTX) reported its share capital and voting rights position as of July 31, 2026, in line with articles L.233-8 II of the French Commercial Code and article 223-16 of the General Regulation of the French Financial Markets Authority. The company had 50,833,462 shares outstanding. Total theoretical voting rights were 54,534,179, while total exercisable voting rights at shareholder meetings were 54,512,061, reflecting the exclusion of shares with suspended voting rights such as treasury shares. Nanobiotix remains listed on Euronext Paris and the Nasdaq Global Select Market.

Nanobiotix S.A. has an institutional holder group led by Invus Public Equities, L.P. reporting beneficial ownership of 4,483,275 ordinary shares and 345,099 pre-funded warrants, each exercisable for one share at Euro 0.03 per share and expiring May 26, 2036. Based on 50,807,903 shares outstanding as of May 31, 2026, plus the warrant shares, the Invus-related reporting persons each may be deemed to beneficially own 4,828,374 shares, or 9.4% of the company. The group reports sole voting and dispositive power over these securities and certifies that the holdings are not for the purpose of changing or influencing control. Nanobiotix ADSs, each representing one ordinary share, trade under the symbol NBTX and use CUSIP 63009J107.

Nanobiotix S.A. reported its share capital and voting rights position as of June 30, 2026, showing 50,825,682 shares outstanding.

The company reported 54,486,890 theoretical voting rights, used as the basis for calculating threshold crossings, and 54,464,772 exercisable voting rights, which exclude shares held in treasury where voting rights are suspended. Nanobiotix is a late-stage clinical biotechnology company headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market.

Qatar Investment Authority reports beneficial ownership of 3,532,517 Nanobiotix SA Depositary Receipt S ADRs, representing 7.0% of this class. The position carries sole voting and sole dispositive power over all reported ADRs, with no shared voting or dispositive authority.

The ADRs are held through two wholly owned subsidiaries of Qatar Investment Authority: QH Oil Investment LLC, holding 3,304,839 ADRs, and Q Dutis Holding LLC, holding 227,678 ADRs.

Nanobiotix S.A. reports its share capital and voting rights as of May 31, 2026. The company lists 50,807,903 shares outstanding, with total theoretical voting rights of 54,304,858 and total exercisable voting rights of 54,282,740.

Theoretical voting rights include all shares with attached voting rights, even when suspended, and are used to calculate regulatory threshold crossings in France. Exercisable voting rights exclude shares with suspended voting rights, such as treasury shares, to reflect the votes that can actually be cast at a shareholders’ meeting.

Nanobiotix reported its first quarter 2026 update, highlighting stronger funding and progress in its lead oncology programs. The company completed a follow-on offering in May 2026 for aggregate gross proceeds of approximately €86.1 million.

Nanobiotix held €42.1 million in cash and cash equivalents as of March 31, 2026, and believes its financial resources will support operations into 2029. Early Part 1 data from the J&J-sponsored CONVERGE study in unresectable Stage 3 NSCLC showed an overall response rate of 85.7% and complete response rate of 57.1% in 7 patients, with an acceptable safety profile, while a protocol amendment was accepted for the pivotal NANORAY-312 Phase 3 trial.

Nanobiotix S.A. filed a Form 6-K to share that it has been included in the Euronext Tech Leaders segment and added to the Euronext Tech Leaders Index. This Euronext initiative highlights innovative, high-growth European technology companies and aims to increase their visibility with international investors.

The company describes itself as a late-stage clinical biotechnology business pioneering physics-based nanotherapeutic approaches for cancer and other major diseases. Headquartered in Paris and listed on Euronext Paris and the Nasdaq Global Select Market, Nanobiotix owns more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.

Nanobiotix S.A. has entered an underwriting agreement for a global equity offering combining U.S. and European tranches plus long-dated pre-funded warrants. The deal includes 225,373 ADSs in the United States at $38.98 per ADS and 1,959,289 ordinary shares in Europe at €33.60 per share, alongside 345,099 pre-funded warrants, each exercisable for one ordinary share at €0.03.

The underwriters also exercised a U.S. over-allotment option for 33,805 additional ADSs at $38.98 per ADS, with the overall global offering expected to close on or about May 26, 2026. The pre-funded warrants are exercisable until May 26, 2036, subject to a Beneficial Ownership Limitation initially set at 9.99% of outstanding ordinary shares, with possible increases up to 19.99% of shares and, for French foreign direct investment purposes, up to 24.99% of voting rights, subject to regulatory conditions.

Nanobiotix has closed a global equity offering raising aggregate gross proceeds of about $100 million (approximately €86.1 million). The financing comprised 2,218,467 new ordinary shares, including ADSs and Additional ADSs, and 345,099 pre-funded warrants.

The subscription price was €33.60 per ordinary share, equal to an ADS offering price of $38.98, reflecting a 14.92% discount to the recent volume-weighted average share price. Net proceeds are earmarked mainly to advance Nanoprimer and other platforms, support JNJ-1900 (NBTXR3), and for general corporate purposes, and are expected to fund operations into 2029.